Bellerophon Therapeutics Inc. [NASDAQ: BLPH] loss -10.53% on the last trading session, reaching $10.20 price per share at the time. The company report on March 31, 2023 that Bellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial Results.
Completed Enrollment in INOpulse® REBUILD Phase 3 trial; Pivotal Top-line Data Expected in Mid-2023.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Signed License Agreement with Baylor BioSciences to Commercialize INOpulse® in Greater China.
Bellerophon Therapeutics Inc. represents 9.57 million in outstanding shares, while the company has a total market value of $100.67 million with the latest information. BLPH stock price has been found in the range of $9.86 to $11.79.
If compared to the average trading volume of 1.31M shares, BLPH reached a trading volume of 350508 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Bellerophon Therapeutics Inc. [BLPH]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BLPH shares is $24.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BLPH stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Bellerophon Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 11, 2020. While these analysts kept the previous recommendation, Maxim Group raised their target price to Buy. The new note on the price target was released on January 24, 2019, representing the official price target for Bellerophon Therapeutics Inc. stock. Previously, the target price had yet another raise to $4.50, while Ladenburg Thalmann analysts kept a Buy rating on BLPH stock.
The Average True Range (ATR) for Bellerophon Therapeutics Inc. is set at 1.10 The Price to Book ratio for the last quarter was 39.23, with the Price to Cash per share for the same quarter was set at 0.70.
Trading performance analysis for BLPH stock
Bellerophon Therapeutics Inc. [BLPH] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 36.73. With this latest performance, BLPH shares gained by 67.21% in over the last four-week period, additionally plugging by 802.65% over the last 6 months – not to mention a rise of 337.77% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BLPH stock in for the last two-week period is set at 72.33, with the RSI for the last a single of trading hit 70.12, and the three-weeks RSI is set at 73.29 for Bellerophon Therapeutics Inc. [BLPH]. The present Moving Average for the last 50 days of trading for this stock 4.44, while it was recorded at 9.84 for the last single week of trading, and 2.07 for the last 200 days.
Bellerophon Therapeutics Inc. [BLPH]: A deeper dive into fundamental analysis
Return on Equity for this stock declined to -164.21, with Return on Assets sitting at -113.94.
Bellerophon Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.40.
An analysis of insider ownership at Bellerophon Therapeutics Inc. [BLPH]
There are presently around $11 million, or 31.20% of BLPH stock, in the hands of institutional investors. The top three institutional holders of BLPH stocks are: WELLS FARGO & COMPANY/MN with ownership of 191,065, which is approximately -4.498% of the company’s market cap and around 0.70% of the total institutional ownership; RENAISSANCE TECHNOLOGIES LLC, holding 171,799 shares of the stock with an approximate value of $1.96 million in BLPH stocks shares; and VANGUARD GROUP INC, currently with $1.66 million in BLPH stock with ownership of nearly -57.76% of the company’s market capitalization.
Positions in Bellerophon Therapeutics Inc. stocks held by institutional investors increased at the end of Thursday and at the time of the Thursday reporting period, where 8 institutional holders increased their position in Bellerophon Therapeutics Inc. [NASDAQ:BLPH] by around 94,542 shares. Additionally, 9 investors decreased positions by around 252,967 shares, while 9 investors held positions by with 577,994 shares. The mentioned changes placed institutional holdings at 925,503 shares, according to the latest SEC report filing. BLPH stock had 7 new institutional investments in for a total of 94,535 shares, while 1 institutional investors sold positions of 14,663 shares during the same period.